论文部分内容阅读
目的探讨乳腺亚临床病灶的性质及Encor微创旋切术对其的诊治价值。方法对630例964个乳腺亚临床病灶行B超引导下Encor微创旋切术,分析术后病理诊断结果。结果 964个亚临床病灶成功切除。术后病理示纤维腺瘤686个(71.2%),囊肿132个(13.7%),乳管内乳头状瘤45个(4.7%),腺病瘤89个(9.2%),乳腺癌12个(1.2%)。136个BI-RADSⅣ级病灶中3个确诊为乳腺癌;而BI-RADSⅡ～Ⅲ级中,9个病灶术后病理诊断为乳腺癌,漏诊率为1.09%(9/828)。良性病例随访至今,定期复查超声及乳腺钼靶X线摄片未见复发及恶性病变出现。结论 B超诊断的良性乳腺亚临床病灶中仍有漏诊乳腺癌可能,需要密切随访。辅助Encor活检对亚临床病灶的切检效果准确、可靠,是“一步手术”诊治的最佳选择,可降低早期乳腺癌漏诊的风险。
Objective To investigate the nature of subclinical breast lesions and the value of Encor minimally invasive polypectomy. Methods 630 cases of 964 breast subclinical lesions under the guidance of Encor minimally invasive biopsy, postoperative pathological diagnosis. Results 964 subclinical lesions were successfully resected. There were 686 (71.2%) fibroadenomas, 132 (13.7%) cysts, 45 (4.7%) intraductal papillomas, 89 (9.2%) adenomas and 12 %). Three of the 136 BI-RADS Ⅳ lesions were diagnosed as breast cancer. Nine of the BI-RADS Ⅱ-Ⅲ lesions were pathologically diagnosed as breast cancer with a missed diagnosis rate of 1.09% (9/828). Follow-up of benign cases so far, regular review of ultrasound and mammography mammography no recurrence and malignant lesions. Conclusions There is still a possibility of missed diagnosis of breast cancer in B-ultrasound diagnosis of benign breast subclinical lesions, which requires close follow-up. Assisted Encor Biopsy is accurate and reliable for the sub-clinical lesion and is the best choice for “one-step operation” to reduce the risk of missed diagnosis of early breast cancer.